Business
Product Development Progress
Product Development Progress.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \n \n RNS Number : 6861U\n SkinBioTherapeutics PLC\n 31 July 2020\n \n \n \n \n 31 July 2020\n \n \n SkinBioTherapeutics plc\n \n \n (\"SkinBioTherapeutics\" or \"the Company\" or \"the Group\")\n \n \n Product Development Progress\n \n \n \n \n \n · Cosmetic programme achieves key scientific milestones with its partner Sederma (Croda)\n \n ·Company targeting an accelerated psoriasis food supplement trial in early 2021 to facilitate launch of AxisBiotix product\n \n \n SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, provides an update on its product development programmes. \n \n \n \n \n \n Cosmetic skincare\n \n \n Sederma, the division of Croda Plc that specialises in the manufacture of bioactive ingredients for the cosmetic industry, has updated the Company on progress of its ongoing collaboration and confirmed that;\n \n \n \n ·\n Sederma has successfully replicated the lysate manufacturing process and achieved the same performance from the SkinBiotix® technology as established by the Company\n \n · \n Sederma is now working to validate scale up of the manufacturing process at different volume levels\n \n \n · \n The project is progressing in line with the original plan and has not been adversely impacted by COVID-19.\n \n \n Sederma will be responsible for the development, manufacture and commercialisation of the SkinBiotix\n ®\n technology, with any products resulting from this programme being sold to Croda's global portfolio of Personal Care customers. SkinBioTherapeutics will be paid tiered royalties based on global sales revenues on any licensed products derived from the partnership.\n \n \n \n \n \n Acceleration of psoriasis food supplement trial\n \n \n In February 2020, the Company signed a development agreement with Winclove for a probiotic food supplement to help manage the symptoms associated with the skin condition, psoriasis. \n \n \n \n \n \n In July (RNS 7 July 2020) the Company reported that several months ahead of schedule, Winclove had successfully combined and formulated the blend as a probiotic food supplement, to be known as AxisBiotix\n ™Ps. \n \n \n \n \n \n In light of the current restrictions with regards to non-COVID related human stu...